Bone Marrow Transplantation

Top Story

Autologous, nonmyeloablative HSCT show promise for advanced multiple myeloma

February 11, 2016

A frontline transplant tandem approach consisting of autologous and nonmyeloablative allogeneic transplantation demonstrated promising OS and PFS among patients with multiple myeloma, according to phase 2 study results.

Although new drug therapies and autologous hematopoietic stem cell transplantation have improved outcomes for multiple myeloma, the condition remains largely incurable, according to study background.

In the Journals

Experts reveal ‘troubling’ industry-employed strategies to delay availability of generic cancer drugs

February 8, 2016
Pharmaceutical companies have employed several strategies — including reverse payment, patent settlements and “product hopping” — to prevent…
In the Journals

HSCT may improve DFS, OS in older patients with AML

February 1, 2016
Reduced-intensity conditioning hematopoietic stem cell transplantation appeared well tolerated and associated with favorable outcomes in selected older patients with…
In the Journals

Grafts from younger, HLA-matched donors may improve HSCT outcomes

January 22, 2016
Factors such as donor age and donor–recipient HLA-match appeared to contribute to long-term survival among patients undergoing unrelated-donor transplantation for…
CME

The Patient with Myelofibrosis

No commercial support for this activity.

Myelofibrosis is caused by abnormal stem cells in the bone marrow that cause the uncontrolled production of mature…
More »
Meeting News CoverageVideo

CD19-targeted T-cells show potential in B-ALL, allogeneic stem cell transplantation

June 19, 2014
More »
Featured
CME

The Patient with Severe Leukocytosis

No commercial support for this activity.

Currently five tyrosine kinase inhibitors are available for use in patients with chronic myeloid leukemia (CML)…
More »
In the Journals

Autologous, nonmyeloablative HSCT show promise for advanced multiple myeloma

February 11, 2016
A frontline transplant tandem approach consisting of autologous and nonmyeloablative allogeneic transplantation demonstrated promising OS and PFS…
In the Journals

Experts reveal ‘troubling’ industry-employed strategies to delay availability of generic cancer drugs

February 8, 2016
Pharmaceutical companies have employed several strategies — including reverse payment, patent settlements and “product hopping”…
In the Journals

HSCT may improve DFS, OS in older patients with AML

February 1, 2016
Reduced-intensity conditioning hematopoietic stem cell transplantation appeared well tolerated and associated with favorable outcomes in selected…
In the Journals

Grafts from younger, HLA-matched donors may improve HSCT outcomes

January 22, 2016
Factors such as donor age and donor–recipient HLA-match appeared to contribute to long-term survival among patients undergoing unrelated-donor…
Video

VIDEO: Effort to systematize approach to medicine has ‘taken on a life of its own’

January 20, 2016
HemOnc Today’s Chief Medical Editors — Derek Raghavan, MD, PhD, and John Sweetenham, MD — discuss the proliferation of guidelines…

Aflac Cancer and Blood Disorders Center names director

January 18, 2016
Douglas Graham, MD, PhD, has been named director of the Aflac Cancer and Blood Disorders Center of Children’s Healthcare of Atlanta.Graham…
CME

The Patient with Severe Leukocytosis

January 15, 2016 Expires: 1/15/2017
Currently five tyrosine kinase inhibitors are available for use in patients with chronic myeloid leukemia (CML). Although imatinib has been the…
In the Journals

Stem cell sources for HSCT vary by region, gross national income

January 12, 2016
The use of peripheral blood stem cells for allogeneic hematopoietic stem cell transplantation in patients with bone marrow failure appeared more…

ASCO elects four members to board of directors

January 7, 2016
Four oncology leaders have been elected to ASCO’s board of directors.The new members of the board of directors will begin 4-year terms in June.
In the Journals

Addition of ATG reduces incidence of chronic GVHD in patients with acute leukemia

January 6, 2016
The inclusion of antihuman T-lymphocyte immune globulin in a myeloablative conditioning regimen for patients with acute leukemia significantly…
More Headlines »
morganatic-roan morganatic-roan